Article

[Clinical study of cryoablation in the salvage treatment of stage III non-small cell lung cancer].

Department of Interventional Therapeutics, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China.
Zhonghua yi xue za zhi 08/2011; 91(31):2205-7. pp.2205-7
Source: PubMed

ABSTRACT To evaluate the efficacy and safety of argon-helium cryoablation as a salvage therapy for the failure cases of non-small cell lung cancer (NSCLC) after radiochemotherapy.
A total of 12 NSCLC patients (stage III) with a diagnosis of recurrence after radiochemotherapy received cryoablation. The endpoint objectives were overall response rate (RR), clinical benefit rate (CBR), 1-year survival rate, quality of life (QOL) and safety profile.
Among them, the overall response rate was 6/12 cases and the clinical benefit rate 7/12 cases at 12 months post-cryoablation. The 1-year survival rate was 10/12 cases. No significant complications or adverse reactions occurred during the process of cryoablation. As shown by the QOL score, the quality of life was satisfactory.
As a salvage treatment for the recurrence NSCLC cases after radiochemotherapy, cryoablation may achieve a high response rate, a favorable 1-year survival rate and a high safety profile. It has excellent prospects for clinical applications.

0 0
 · 
0 Bookmarks
 · 
33 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

1-year survival rate
 
12 months post-cryoablation
 
adverse reactions
 
argon-helium cryoablation
 
clinical applications
 
clinical benefit rate
 
clinical benefit rate 7/12 cases
 
cryoablation
 
efficacy
 
endpoint objectives
 
favorable 1-year survival rate
 
non-small cell lung cancer
 
QOL
 
QOL score
 
radiochemotherapy
 
response rate
 
safety profile
 
salvage therapy
 
significant complications
 
stage III